These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1433183)

  • 1. Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
    Yu PH; Davis BA; Boulton AA
    J Med Chem; 1992 Oct; 35(20):3705-13. PubMed ID: 1433183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliphatic propargylamines, a new series of potent selective, irreversible non-amphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications.
    Yu PH; Davis BA; Boulton AA
    Adv Exp Med Biol; 1995; 363():17-23. PubMed ID: 7618520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity.
    Yu PH; Davis BA; Boulton AA
    Biochem Pharmacol; 1993 Aug; 46(4):753-7. PubMed ID: 8363648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors.
    Yu PH; Davis BA; Durden DA; Barber A; Terleckyj I; Nicklas WG; Boulton AA
    J Neurochem; 1994 Feb; 62(2):697-704. PubMed ID: 8294932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inversion of selectivity of N-substituted propargylamine monoamine oxidase inhibitors following structural modifications to quaternary salts.
    Yu PH; Davis BA
    Int J Biochem Cell Biol; 1999 Dec; 31(12):1391-7. PubMed ID: 10641793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
    Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M
    J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
    Di Pietro O; Alencar N; Esteban G; Viayna E; Szałaj N; Vázquez J; Juárez-Jiménez J; Sola I; Pérez B; Solé M; Unzeta M; Muñoz-Torrero D; Luque FJ
    Bioorg Med Chem; 2016 Oct; 24(20):4835-4854. PubMed ID: 27396685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications.
    Yu PH; Davis BA; Boulton AA; Zuo DM
    J Neural Transm Suppl; 1994; 41():397-406. PubMed ID: 7931256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Huleatt PB; Khoo ML; Chua YY; Tan TW; Liew RS; Balogh B; Deme R; Gölöncsér F; Magyar K; Sheela DP; Ho HK; Sperlágh B; Mátyus P; Chai CL
    J Med Chem; 2015 Feb; 58(3):1400-19. PubMed ID: 25627172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
    Youdim MB; Gross A; Finberg JP
    Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of monoamine oxidase by clorgyline analogues.
    O'Brien EM; Tipton KF; Meroni M; Dostert P
    J Neural Transm Suppl; 1994; 41():295-305. PubMed ID: 7931241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-(E)-Styryl-2H-chromene derivatives as potent and selective monoamine oxidase B inhibitors.
    Takao K; Yahagi H; Uesawa Y; Sugita Y
    Bioorg Chem; 2018 Apr; 77():436-442. PubMed ID: 29448189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties.
    Yu PH; Davis BA; Zhang X; Zuo DM; Fang J; Lai CT; Li XM; Paterson IA; Boulton AA
    Prog Brain Res; 1995; 106():113-21. PubMed ID: 8584647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
    Xu YX; Wang H; Li XK; Dong SN; Liu WW; Gong Q; Wang TD; Tang Y; Zhu J; Li J; Zhang HY; Mao F
    Eur J Med Chem; 2018 Jan; 143():33-47. PubMed ID: 29172081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R; Lecht S; Lazarovici P
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.
    Pisani L; Muncipinto G; Miscioscia TF; Nicolotti O; Leonetti F; Catto M; Caccia C; Salvati P; Soto-Otero R; Mendez-Alvarez E; Passeleu C; Carotti A
    J Med Chem; 2009 Nov; 52(21):6685-706. PubMed ID: 19810674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase.
    Chimenti F; Bolasco A; Manna F; Secci D; Chimenti P; Befani O; Turini P; Giovannini V; Mondovì B; Cirilli R; La Torre F
    J Med Chem; 2004 Apr; 47(8):2071-4. PubMed ID: 15056004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.